https://scholars.lib.ntu.edu.tw/handle/123456789/537048
標題: | Natural history and clinical management of chronic hepatitis B virus infection in children | 作者: | MEI-HWEI CHANG | 關鍵字: | Adolescents; Children; Chronic hepatitis B; Hepatitis B e antigen; Hepatitis B virus | 公開日期: | 2008 | 卷: | 2 | 期: | SUPPL. 1 | 起(迄)頁: | S28-S36 | 來源出版物: | Hepatology International | 摘要: | Hepatitis B virus (HBV) infection may cause acute, fulminant, or chronic hepatitis, leading to liver cirrhosis or hepatocellular carcinoma. Despite the availability of effective vaccine, HBV infection during infancy or early childhood is common in areas of high endemicity. In these regions, mother-to-infant transmission accounts for approximately 50% of chronic infections. Although the natural history of HBV infection in adults is well characterized, little information is available in the literature regarding the natural history of HBV infection in children. Similar to infection in adults, chronic HBV infection in children can be divided into distinct phases: immune tolerant, immune clearance, and inactive carrier state. However, acute exacerbation, with reactivation of HBV replication and re-elevation of alanine aminotransferase levels after hepatitis B e antigen seroconversion, is relatively rare in children, in comparison to adults. Although several potent antiviral agents are now available for the treatment of chronic hepatitis B, experience with these agents in the pediatric setting is limited. To date, conventional interferon α and lamivudine are the only two antiviral agents approved to treat chronic hepatitis B in children. The rapid emergence of resistant HBV associated with long-term lamivudine therapy, as well as poor tolerability associated with conventional interferon α, are factors that should be considered before initiating antiviral therapy. This article reviews current knowledge regarding the natural history and treatment of chronic hepatitis B in children. Factors that affect the natural history of HBV infection in children are also reviewed. ? Asian Pacific Association for the Study of the Liver 2008. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-69749101323&doi=10.1007%2fs12072-008-9050-9&partnerID=40&md5=352cd3dbd1b943c16b7976b62f28f38e https://scholars.lib.ntu.edu.tw/handle/123456789/537048 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-008-9050-9 | SDG/關鍵字: | adefovir; alanine aminotransferase; alpha interferon; alpha2a interferon; antivirus agent; entecavir; hepatitis B surface antigen; hepatitis B(e) antigen; lamivudine; peginterferon alpha; placebo; telbivudine; bone marrow suppression; child; child care; clinical trial; combination chemotherapy; depression; disease course; drug absorption; drug bioavailability; drug indication; fever; flu like syndrome; gene mutation; genotype; hair loss; hepatitis B; Hepatitis B virus; histopathology; human; immunological tolerance; injection pain; injection site pain; leukopenia; liver cell carcinoma; liver fibrosis; malaise; monotherapy; mutant; nephrotoxicity; nonhuman; perinatal infection; prevalence; priority journal; promoter region; review; risk factor; seroconversion; stop codon; treatment duration; unspecified side effect; virus gene; virus replication; virus transmission |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。